Arming an Anti-CD38 Antibody With Interferon in Myeloma
James R. Berenson, MD, discusses a study presented at the 2013 American Society of Hematology (ASH) Meeting that looked at arming an anti-CD38, myeloma-targeting antibody with interferon.
Clinical Pearls
James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, discusses a study presented at the 2013 American Society of Hematology (ASH) Meeting that looked at arming an anti-CD38, myeloma-targeting antibody with interferon.
- Interferon was used to treat myeloma (maintain remissions) in the 1980s and 1990s
- When paired with interferon, this anti-CD38 agent can enhance tumor-specific activity 10,000x compared with native interferon
- This pairing cured multiple tumors in mice
- It remains unknown if this pairing will have effects on immune and other cells in the human body
<<<
Khouri Discusses Selinexor Dosing and Management Approaches for R/R MM
July 22nd 2024During a Case-Based Roundtable® event, Jack Khouri, MD, and participants discussed the use of selinexor with dose modifications to manage toxicity in patients with relapsed/refractory multiple myeloma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Evolving Roles of Transplant and Quadruplet Therapy in Multiple Myeloma
July 15th 2024During a Case-Based Roundtable® event, Adam D. Cohen, MD, discussed triplet vs quadruplet options for a patient with transplant eligible multiple myeloma and NCCN recommendations in the first article of a 2-part series.
Read More
